Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Transcription profiling of skin from patients with moderate to severe atopic dermatitis before and after treatment with IL-4R? inhibitor dupilumab (REGN668/SAR231893)


ABSTRACT: Atopic dermatitis (AD) is the most common inflammatory skin disease, with high unmet need for new therapies that are safe for chronic use. Emerging data suggest that TH2-cytokines play important roles in a variety of allergic and atopic conditions, including asthma and AD. In early phase clinical trials, dupilumab (a fully human monoclonal antibody against IL-4R? that potently blocks IL-4 and IL-13 signaling) rapidly and markedly improved clinical measures in adults with either asthma (with elevated eosinophil counts) or moderate-to-severe AD. The pathomechanisms that may be impacted by IL-4/13 blockade in these disease settings have not yet been characterized in detail. Transcriptome analyses in pre- and post-treatment skin biopsies from patients with moderate-to-severe AD treated with dupilumab or placebo in two completed clinical trials 18 Patients with AD treated with dupilumab or placebo. 28 biopsies in lesional (LS) Skin (16 pre-treatment and 12 post-treatment). 12 biopsies in non-lesional (NL) Skin (7 pre-treatment and 5 post treatment)

ORGANISM(S): Homo sapiens

SUBMITTER: Mayte Suarez-Farinas 

PROVIDER: E-GEOD-59294 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications

Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis.

Hamilton Jennifer D JD   Suárez-Fariñas Mayte M   Dhingra Nikhil N   Cardinale Irma I   Li Xuan X   Kostic Ana A   Ming Jeffrey E JE   Radin Allen R AR   Krueger James G JG   Graham Neil N   Yancopoulos George D GD   Pirozzi Gianluca G   Guttman-Yassky Emma E  

The Journal of allergy and clinical immunology 20141201 6


<h4>Background</h4>Severe atopic dermatitis (AD) has a high unmet need for effective and safe therapeutics. In early-phase trials, dupilumab, a fully human mAb targeting IL-4 receptor α, markedly improved disease activity, but the effect of IL-4/IL-13 blockade on AD at the molecular level has not been characterized.<h4>Objectives</h4>We sought to evaluate dupilumab modulation of the AD molecular signature.<h4>Methods</h4>We performed transcriptomic analyses of pretreatment and posttreatment skin  ...[more]

Similar Datasets

2014-12-04 | GSE59294 | GEO
2024-08-22 | PXD050245 | Pride
2019-05-02 | GSE130588 | GEO
2020-09-01 | GSE157194 | GEO
2015-09-29 | GSE65832 | GEO
2016-03-08 | E-GEOD-75890 | biostudies-arrayexpress
2023-01-16 | GSE185764 | GEO
2012-06-01 | E-MTAB-729 | biostudies-arrayexpress
2011-07-01 | E-GEOD-27887 | biostudies-arrayexpress
2020-10-31 | GSE160501 | GEO